Pro Dex Inc
PDEX Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 26, 2026
$60.66
KIRA · Stoqly’s AI analyst, in plain words
- Pro Dex Inc had $77.5M of revenue in fiscal 2026, up 16.5% on the year before. Over five years, revenue changed +15.3% a year on average.
- Its operating margin was 16.8%, up 0.7 pts: of every 100 in sales, about 17 is left after running the business.
- Pro Dex Inc made $13.7M of net profit in fiscal 2026. From fiscal 2017 to 2026, diluted EPS grew 14.2% a year.
- Free cash flow was $6.8M in fiscal 2026, 8.7% of revenue.
- Pro Dex Inc returned $3.4M to shareholders in fiscal 2026, 50% of free cash flow. The diluted share count fell 1.3%.
- Pro Dex Inc owes $8.2M more than it holds in cash, about 0.6 years of operating profit.
Market cap
$201M
P/E
14.7x
Revenue
$77.5M
Net income
$13.7M
Free cash flow
$6.8M
Operating margin
16.8%
Pro Dex Inc in 30 seconds · fiscal 2026
Are sales growing?
+16.5%
Yes. Sales grew 16.5% last year.
Does it make a profit?
17.6%
Yes. It keeps 17.6% of every sale as profit.
Does profit turn into cash?
8.7%
Partly. 8.7% of sales ends up as free cash.
Is debt under control?
0.6x
Yes. It could repay its debt with 0.6 years of operating profit.
How healthy are the accounts?
7 / 9
Solid. It passes 7 of 9 health tests.
How is the share priced?
14.7x
One share costs 14.7 times its yearly profit per share.
What Pro Dex Inc does
No business description yet.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 10-K · Sep 3, 2026
- Legal name
- PRO DEX INC
- CIK
- 0000788920
Pro Dex Inc · PDEX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $42.0M | $46.1M | $53.8M | $66.6M | $77.5M |
| Revenue growth | 10.5% | 9.6% | 16.8% | 23.7% | 16.5% |
| Gross margin | 31.2% | 27.7% | 27.0% | 29.3% | 31.4% |
| Operating margin | 12.2% | 12.5% | 13.3% | 16.1% | 16.8% |
| Net income | $4.6M | $7.1M | $2.1M | $9.0M | $13.7M |
| Net margin | 10.9% | 15.3% | 4.0% | 13.5% | 17.6% |
| Diluted EPS | $1.21 | $1.95 | $0.60 | $2.67 | $4.12 |
| Cash | |||||
| Cash from operations | −$0.8M | $5.5M | $6.2M | −$1.7M | $7.2M |
| Capital expenditure | $1.6M | — | — | $1.2M | $0.5M |
| Free cash flow | −$2.5M | — | — | −$2.9M | $6.8M |
| FCF margin | −5.9% | — | — | −4.4% | 8.7% |
| Share buybacks | $1.6M | $1.5M | $3.5M | $3.5M | $3.4M |
| Share count change | −4.4% | −3.4% | −1.8% | −5.9% | −1.3% |
| Debt and strength | |||||
| Cash and short-term investments | $1.6M | $4.1M | $6.8M | $7.2M | $9.3M |
| Debt incl. finance leases | $13.6M | $12.8M | $12.0M | $15.4M | $17.5M |
| Shareholders' equity | $25.4M | $31.6M | $30.9M | $36.6M | $47.6M |
| Net debt / EBITDA | 2.0x | 1.3x | 0.6x | 0.7x | 0.6x |
| Current ratio | 2.7x | 3.2x | 2.8x | 3.2x | 4.1x |
| Interest coverage | 11.0x | 10.8x | 12.9x | 12.9x | 16.0x |
| Returns and quality | |||||
| Return on capital | 11.0% | 10.7% | 16.1% | 17.7% | 17.7% |
| Return on equity | 19.6% | 24.8% | 6.8% | 26.6% | 32.4% |
| Return on tangible equity | 18.1% | 22.5% | 6.9% | 24.5% | 33.8% |
| Piotroski F-score | 3 | 7 | 6 | 6 | 7 |
| Altman Z'' | 5.7 | 6.6 | 7.1 | 8.2 | 8.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$2.0M
3 insiders
Of sales under plans
91%
$1.8M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Pro Dex Inc · PDEX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $60.66 a share, the company is worth $201M: 14.7 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0000788920). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.